<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2010</study_start_year><condition>Colorectal Carcinoma</condition><condition>Colorectal Tumors</condition><condition>Neoplasms, Colorectal</condition><condition>Colorectal Cancer</condition><condition>Colorectal Neoplasms</condition><disease>Colorectal Carcinoma</disease><disease>Colorectal Tumors</disease><disease>Neoplasms, Colorectal</disease><disease>Colorectal Cancer</disease><disease>Colorectal Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2090309</full_dataset_link><location>Australia</location><study_start_month>6</study_start_month><keyword>Irinotecan</keyword><keyword>Panitumumab</keyword><keyword>Everolimus</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer</name><description>This study will assess the safety of panitumumab, irinotecan and everolimus when given in combination to treat advanced colorectal cancer</description><dates><creation>2010-06-15</creation></dates><accession>2090309</accession><cross_references><ClinicalTrials___gov>NCT01139138</ClinicalTrials___gov></cross_references></HashMap>